New Hope for Serious Infections

Cidara is a clinical-stage biotechnology company focused on the development of novel anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives.

Company OverviewRezafunginCloudbreak

Cidara is a clinical-stage biotechnology company focused on the development of novel anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives.

About UsRezafunginCloudbreak™

Cidara News + Events

Preventing Invasive Fungal Infections in Hematologic Patients

Oncology Times

Download PDF

There is an urgent and growing need not only for improved anti-infectives but also for entirely new therapeutic approaches to treat and prevent fungal, bacterial, and viral pathogens, particularly for today’s increasingly complex and immunocompromised patients.

Our initial portfolio is comprised of proprietary product and development candidates for the treatment and prevention of serious infections.

Rezafungin (CD101 IV)

Rezafungin, a long-acting echinocandin antifungal, is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections.

Cloudbreak Platform

The Cloudbreak immunotherapy discovery platform is a fundamentally new approach for the treatment of infectious disease that, in a single molecule, both directly kills and directs the immune system to attack microbial pathogens.